Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPD
Gaetano Caramori,1 Kian Fan Chung,2 Ian M Adcock2 1Centro Interdipartimentale per lo Studio delle Malattie Infiammatorie delle Vie Aeree e Patologie Fumo-correlate (CEMICEF; formerly Centro di Ricerca su Asma e BPCO), Sezione di Medicina Interna e Cardiorespiratoria, Università di Ferrar...
Main Authors: | Caramori G, Chung KF, Adcock IM |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2014-02-01
|
Series: | International Journal of COPD |
Online Access: | http://www.dovepress.com/profile-of-fluticasone-furoatevilanterol-dry-powder-inhaler-combinatio-a15930 |
Similar Items
-
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
by: Nicola C. Day, et al.
Published: (2020-06-01) -
Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol
by: Molino A, et al.
Published: (2018-06-01) -
Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study
by: Peter R. Bremner, et al.
Published: (2018-01-01) -
Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk
by: Covelli H, et al.
Published: (2015-12-01) -
Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapy
by: Lal C, et al.
Published: (2016-12-01)